File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer

TitleIncreased Id-1 expression is significantly associated with poor survival of patients with prostate cancer
Authors
Issue Date2007
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/humpath
Citation
Human Pathology, 2007, v. 38 n. 9, p. 1321-1329 How to Cite?
AbstractThe levels of Id-1 (inhibitor of DNA binding or inhibitor of cell differentiation) expression in a series of prostate cell lines and in an archival set of prostate tissues were examined. Western blot analysis showed that the level of Id-1 expressed in the androgen sensitive cell line LNCaP was 1.2 ± 0.2 times that detected in the benign cell line PNT-2. The level of Id-1 increased further to 1.8 ± 0.2 and 2.9 ± 0.3 in the androgen-insensitive cell lines Du-145 and PC-3, respectively. Immunohistochemical staining with Id-1 antibody performed on 113 cases of prostate tissues showed that among the 7 normal cases, 6 (86%) stained either negative or weakly positive whereas only 1 (14%) stained moderately positive. Among the 36 benign prostatic hyperplasia (BPH) samples, 34 (94%) stained either negative or weakly positive; only 1 (3%) stained moderately and 1 (3%) stained strongly. Of the 70 carcinomas, 8 (11.5%) stained weakly, 34 (48.5%) stained moderately, and 28 (40%) stained strongly positive. The intensity of Id-1 staining in carcinomas was significantly stronger than that detected in the normal prostate and BPH (χ2 test, P < .001) and it was significantly increased as the increasing malignancy of carcinomas measured by Gleason score (χ2 test, P < .001). The intensity of Id-1 staining was partially associated with the levels of prostate-specific antigen, but not related to the level of androgen receptor. Kaplan-Meier survival curve analysis showed that, similar to Gleason scores, overexpression of Id-1 was significantly associated with the reduced length of patient survival (log-rank test, P = .01). These results suggest that Id-1 is a useful prognostic marker to predict the outcomes of patients with prostate cancer. © 2007 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/149673
ISSN
2015 Impact Factor: 2.791
2015 SCImago Journal Rankings: 1.363
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorForootan, SSen_US
dc.contributor.authorWong, YCen_US
dc.contributor.authorDodson, Aen_US
dc.contributor.authorWang, Xen_US
dc.contributor.authorLin, Ken_US
dc.contributor.authorSmith, PHen_US
dc.contributor.authorFoster, CSen_US
dc.contributor.authorKe, Yen_US
dc.date.accessioned2012-06-26T05:56:52Z-
dc.date.available2012-06-26T05:56:52Z-
dc.date.issued2007en_US
dc.identifier.citationHuman Pathology, 2007, v. 38 n. 9, p. 1321-1329en_US
dc.identifier.issn0046-8177en_US
dc.identifier.urihttp://hdl.handle.net/10722/149673-
dc.description.abstractThe levels of Id-1 (inhibitor of DNA binding or inhibitor of cell differentiation) expression in a series of prostate cell lines and in an archival set of prostate tissues were examined. Western blot analysis showed that the level of Id-1 expressed in the androgen sensitive cell line LNCaP was 1.2 ± 0.2 times that detected in the benign cell line PNT-2. The level of Id-1 increased further to 1.8 ± 0.2 and 2.9 ± 0.3 in the androgen-insensitive cell lines Du-145 and PC-3, respectively. Immunohistochemical staining with Id-1 antibody performed on 113 cases of prostate tissues showed that among the 7 normal cases, 6 (86%) stained either negative or weakly positive whereas only 1 (14%) stained moderately positive. Among the 36 benign prostatic hyperplasia (BPH) samples, 34 (94%) stained either negative or weakly positive; only 1 (3%) stained moderately and 1 (3%) stained strongly. Of the 70 carcinomas, 8 (11.5%) stained weakly, 34 (48.5%) stained moderately, and 28 (40%) stained strongly positive. The intensity of Id-1 staining in carcinomas was significantly stronger than that detected in the normal prostate and BPH (χ2 test, P < .001) and it was significantly increased as the increasing malignancy of carcinomas measured by Gleason score (χ2 test, P < .001). The intensity of Id-1 staining was partially associated with the levels of prostate-specific antigen, but not related to the level of androgen receptor. Kaplan-Meier survival curve analysis showed that, similar to Gleason scores, overexpression of Id-1 was significantly associated with the reduced length of patient survival (log-rank test, P = .01). These results suggest that Id-1 is a useful prognostic marker to predict the outcomes of patients with prostate cancer. © 2007 Elsevier Inc. All rights reserved.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/humpathen_US
dc.relation.ispartofHuman Pathologyen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshGene Expression Regulation, Neoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshInhibitor Of Differentiation Protein 1 - Analysisen_US
dc.subject.meshKaplan-Meier Estimateen_US
dc.subject.meshMaleen_US
dc.subject.meshPredictive Value Of Testsen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProstate-Specific Antigen - Blooden_US
dc.subject.meshProstatic Neoplasms - Blood - Chemistry - Mortality - Pathologyen_US
dc.subject.meshTumor Markers, Biological - Analysisen_US
dc.titleIncreased Id-1 expression is significantly associated with poor survival of patients with prostate canceren_US
dc.typeArticleen_US
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_US
dc.identifier.authorityWong, YC=rp00316en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.humpath.2007.02.011en_US
dc.identifier.pmid17599389-
dc.identifier.scopuseid_2-s2.0-34547842098en_US
dc.identifier.hkuros147315-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34547842098&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume38en_US
dc.identifier.issue9en_US
dc.identifier.spage1321en_US
dc.identifier.epage1329en_US
dc.identifier.isiWOS:000249128100004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridForootan, SS=6505799858en_US
dc.identifier.scopusauthoridWong, YC=7403041798en_US
dc.identifier.scopusauthoridDodson, A=35452418700en_US
dc.identifier.scopusauthoridWang, X=7501854829en_US
dc.identifier.scopusauthoridLin, K=26323246100en_US
dc.identifier.scopusauthoridSmith, PH=7406994487en_US
dc.identifier.scopusauthoridFoster, CS=7401667359en_US
dc.identifier.scopusauthoridKe, Y=7102816291en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats